Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effects of TMS-tACS on Central Autonomic Coupling and Cognition

11. November 2026 aktualisiert von: Xidian University

Modulatory Effects of Combined TMS-tACS Stimulation on Central Autonomic Coupling and Cognitive Function

This study investigates the effects of combined transcranial magnetic stimulation (TMS) and transcranial alternating current stimulation (tACS) on cognitive function and brain-visceral coupling in healthy adults, while exploring the underlying neural mechanisms. Participants will undergo four different neuromodulation conditions, including TMS stimulation, tACS stimulation, combined TMS-tACS stimulation, and sham stimulation. The order of stimulation sessions will be counterbalanced using a randomized Latin square design. During each experimental session, researchers will simultaneously record participants' electroencephalography (EEG), electrocardiography (ECG), respiratory, and gastric signals before and after stimulation, and evaluate cognitive performance through behavioral tasks following stimulation. The primary objective of this study is to investigate how different neuromodulation patterns influence brain-visceral coupling and cognitive function, and to further examine the relationship between changes in central-autonomic interactions and cognitive performance. The findings may provide experimental evidence for understanding the neural mechanisms underlying cognitive regulation and optimizing future non-invasive neuromodulation approaches.

Studienübersicht

Detaillierte Beschreibung

This is an exploratory, randomized, single-blind, sham-controlled, within-subject crossover study designed to investigate the regulatory effects of combined transcranial magnetic stimulation (TMS) and transcranial alternating current stimulation (tACS) on cognitive function and brain-visceral coupling, as well as the underlying neural mechanisms in healthy adults.

Participants will undergo four experimental stimulation conditions, including TMS stimulation, tACS stimulation, combined TMS-tACS stimulation, and sham stimulation. The order of the four stimulation conditions will be balanced using a Latin square design to minimize potential sequence effects, learning effects, and carry-over effects between conditions. A minimum interval of one week will be maintained between experimental sessions. Before stimulation, participants will undergo safety screening and resting motor threshold (RMT) assessment, which will be used to determine individualized stimulation parameters.

During each experimental session, researchers will simultaneously record multimodal physiological signals, including electroencephalography (EEG), electrocardiography (ECG), respiratory signals, and gastric electrical activity, before and after stimulation. Following the intervention, participants will complete cognitive assessment tasks to evaluate changes in cognitive performance induced by different neuromodulation conditions. Participants will not be informed of the specific stimulation condition received in each session to ensure the objectivity and scientific validity of the study.

Primary outcome measures include: brain-visceral coupling metrics, which characterize bidirectional interactions between central neural activity and autonomic physiological rhythms; heartbeat-evoked potentials (HEP), an EEG component time-locked to ECG R-peaks that reflects cortical processing of cardiac afferent information and interoceptive function; heart rate variability (HRV), which reflects autonomic nervous system regulation; and EEG oscillatory activity, which evaluates changes in neural rhythmic dynamics induced by stimulation. Cognitive performance measures will also be collected to investigate the relationship between alterations in brain-visceral coupling and cognitive function.

The primary objective of this study is to systematically examine how different neuromodulation patterns, including TMS, tACS, and combined TMS-tACS stimulation, influence brain-visceral coupling and cognitive function, and to further explore the association between central-autonomic interactions and cognitive performance. The findings may provide experimental evidence for understanding the mechanisms of brain-body interaction and optimizing future non-invasive neuromodulation approaches for cognitive enhancement.

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Shaanxi
      • Xi'an, Shaanxi, China, 71000
        • Rekrutierung
        • Xidian University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 55 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria

  1. Age between 18 and 55 years.
  2. Right-handed individuals.
  3. Body mass index (BMI) between 18 and 24.
  4. No contraindications to transcranial magnetic stimulation (TMS).
  5. No history of clinically significant cardiac disease.
  6. No gastrointestinal disorders.
  7. No respiratory system disorders.
  8. No ear-related diseases.
  9. Voluntary participation and provision of written informed consent.
  10. No participation in other neuromodulation studies within the past month.
  11. Ability to understand the experimental procedures and complete cognitive tasks as required.

Exclusion Criteria

  1. History of epilepsy, traumatic brain injury, severe headache, brain surgery, or other neurological disorders.
  2. History of psychiatric disorders, cognitive impairment, or recent use of medications that may affect central nervous system excitability, including sedatives, antidepressants, or stimulants.
  3. Presence of any contraindications to TMS, including metallic implants, cardiac pacemakers, implantable electronic devices, cochlear implants, or other implanted devices.
  4. Infection, inflammation, ulceration, skin lesions, allergy, reduced sensation, or structural abnormalities of the external ear or stimulation sites.
  5. History of vagus nerve injury or related surgical procedures.
  6. History of cardiovascular diseases, respiratory diseases, gastrointestinal ulcers, or other medical conditions that may affect experimental safety or study outcomes.
  7. Bilateral hand dysfunction preventing completion of experimental tasks.
  8. Current smoking, long-term substance dependence, or recent conditions that may influence study outcomes, such as severe sleep deprivation, alcohol consumption, or excessive fatigue.
  9. Recent participation in other neuromodulation-related experiments.
  10. Refusal to sign the informed consent form.
  11. Any other conditions considered unsuitable for participation by the investigators.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: TMS group

Transcranial Magnetic Stimulation (TMS) Stimulation Condition

Transcranial magnetic stimulation was applied to the dorsolateral prefrontal cortex (DLPFC), targeting the F3 site based on the international 10-20 EEG system. Repetitive transcranial magnetic stimulation (rTMS) was delivered at a frequency of 10 Hz with an intensity of 80% of the resting motor threshold (RMT). The stimulation protocol consisted of 30-second stimulation periods followed by 30-second inter-train intervals, with 15 repeated stimulation cycles and a total of 4,500 pulses. No concurrent tACS stimulation was applied during this condition.

Experimental: tACS group

Transcranial Alternating Current Stimulation (tACS) Stimulation Condition

Transcranial alternating current stimulation (tACS) was applied to the dorsolateral prefrontal cortex (DLPFC), targeting the F3 site according to the international 10-20 EEG system. The stimulation intensity was set at 1 mA and continuously delivered for 15 minutes, including 5-second ramp-up and ramp-down periods. No concurrent transcranial magnetic stimulation was applied during this condition.

Experimental: TMS-tACS combined stimulation group

Combined TMS-tACS Stimulation Condition

Combined transcranial magnetic stimulation and transcranial alternating current stimulation (TMS-tACS) were applied to the dorsolateral prefrontal cortex (DLPFC) targeting the F3 site according to the international 10-20 EEG system. Repetitive transcranial magnetic stimulation (rTMS) was delivered at a frequency of 10 Hz with an intensity of 80% of the resting motor threshold (RMT). The stimulation protocol consisted of 30-second stimulation periods followed by 30-second intervals, with 15 repeated stimulation cycles and a total of 4,500 pulses. Transcranial alternating current stimulation (tACS) was applied simultaneously with an intensity of 1 mA for 15 minutes, including 5-second ramp-up and ramp-down periods. During combined stimulation, TMS pulses were triggered at the peak phase of the tACS sinusoidal waveform to achieve phase-synchronized neuromodulation.

Schein-Komparator: Sham stimulation group

Sham Stimulation Condition

A sham stimulation condition was applied to simulate the sensory experience of active TMS-tACS stimulation without delivering effective neuromodulation. During sham tACS, electrical current was briefly delivered at the beginning of stimulation to mimic the initial skin sensation, while sham TMS was performed using prerecorded stimulation sounds to reproduce the auditory experience associated with active stimulation. No effective magnetic or electrical stimulation was delivered.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Heart-Brain Coupling (Modulation Index)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and electrocardiography (ECG) data will be recorded. Heart-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between cardiac rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Modulation Index)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and respiratory signals will be recorded. Respiration-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between respiratory rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Modulation Index)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and electrogastrography (EGG) data will be recorded. Gastric-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between gastric electrical rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Heart-Brain Coupling (Phase-Locking Value)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and ECG signals will be recorded. Heart-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between cardiac-related rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Heart-Brain Coupling (Mean Vector Length)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and ECG signals will be recorded. Heart-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between cardiac-related phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Phase-Locking Value)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and respiratory signals will be recorded. Respiration-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between respiratory rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Mean Vector Length)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and respiratory signals will be recorded. Respiration-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between respiratory phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Phase-Locking Value)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and EGG signals will be recorded. Gastric-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between gastric electrical rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Mean Vector Length)
Zeitfenster: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and EGG signals will be recorded. Gastric-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between gastric electrical phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
N-back Working Memory Task Performance (d-prime)
Zeitfenster: After each stimulation session, during the post-stimulation cognitive assessment.

Working memory performance will be assessed using the N-back task. The sensitivity index (d-prime, d') will be calculated based on the hit rate and false alarm rate using signal detection theory. Higher d-prime values indicate better working memory performance and greater ability to discriminate target from non-target stimuli.

After each stimulation session, during the post-stimulation cognitive assessment.
Visuospatial Working Memory Task Accuracy
Zeitfenster: After each stimulation session, during the post-stimulation cognitive assessment.

Visuospatial working memory performance will be assessed using a visuospatial memory task. Task accuracy will be calculated as the percentage of correct responses relative to the total number of responses. Accuracy ranges from 0% to 100%, with higher values indicating better visuospatial working memory performance.

After each stimulation session, during the post-stimulation cognitive assessment.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. Dezember 2026

Primärer Abschluss (Geschätzt)

1. April 2027

Studienabschluss (Geschätzt)

1. April 2027

Studienanmeldedaten

Zuerst eingereicht

30. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. November 2026

Zuerst gepostet (Tatsächlich)

17. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren